Progyny Inc (PGNY) FinancialsPGNYProgyny Inc

Progyny, Inc. (PGNY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Fertility benefits services revenue, accounting for 65.7% of total sales, equivalent to $230.21M. Another important revenue stream is Pharmacy benefits services revenue. Understanding this composition is critical for investors evaluating how PGNY navigates market cycles within the Managed Healthcare industry.

Evaluating the bottom line, Progyny, Inc. maintains a gross margin of 25.48%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.41%, while the net margin is 8.00%. These profitability ratios, combined with a Return on Equity (ROE) of 16.24%, provide a clear picture of how effectively PGNY converts its operational activities into shareholder value.

In the context of the broader market, PGNY competes directly with industry leaders such as ANDE and STGW. With a market capitalization of $2.14B, it holds a significant position in the sector. When comparing efficiency, PGNY's gross margin of 25.48% stands against ANDE's 7.22% and STGW's 28.65%. Such benchmarking helps identify whether Progyny, Inc. is trading at a premium or discount relative to its financial performance.

Progyny's Q2 2026 revenue was $350.5 million, a 5% year-over-year increase, with an adjusted EPS of $0.34, exceeding expectations. The gross margin has improved to 25.48%, reflecting strong operational efficiency and demand for its services.